Literature DB >> 14530927

Molecular dynamics study of 4-OH-phenylacetyl- D-Y(Me)FQNRPR-NH2 selectivity to V1a receptor.

Artur Giełdoń1, Rajmund Kaźmierkiewicz, Rafał Slusarz, Marta Pasenkiewicz-Gierula, Jerzy Ciarkowski.   

Abstract

G protein-coupled receptors relay diverse extracellular signals into cells via a common mechanism, involving activation of cytosol G proteins. The mechanism underlies the actions of approximately 50% of all drugs. In this work, we focus on simulating three protein-ligand complexes of the neurohypophyseal hormone analog 4-OH-phenylacetyl- D-Y(Me)FQNRPR-NH2 (I) with the human V1a, V2 and oxytocin receptors. The peptideI is a potent selective V1a receptor antagonist. To obtain relaxed models of the complexes, the following techniques were used: docking ofI into the vasopressin V1a, V2 and oxytocin receptor models, optimization of the geometry of the resulting complexes and molecular dynamics in a fully hydrated 1-palmitoyl-2-oleoyl- sn-glycero-3-phosphatidylcholine lipid bilayer. The results of the simulations allow us to draw some conclusions about the ligand selectivity to V1aR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530927     DOI: 10.1007/s00894-003-0142-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  19 in total

Review 1.  Molecular modelling in structural biology.

Authors:  Mark J Forster
Journal:  Micron       Date:  2002       Impact factor: 2.251

Review 2.  Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs).

Authors:  D C Teller; T Okada; C A Behnke; K Palczewski; R E Stenkamp
Journal:  Biochemistry       Date:  2001-07-03       Impact factor: 3.162

Review 3.  Structure-activity relationships of G protein-coupled receptors.

Authors:  A Ulloa-Aguirre; D Stanislaus; J A Janovick; P M Conn
Journal:  Arch Med Res       Date:  1999 Nov-Dec       Impact factor: 2.235

4.  An extracellular residue determines the agonist specificity of V2 vasopressin receptors.

Authors:  E Ufer; R Postina; V Gorbulev; F Fahrenholz
Journal:  FEBS Lett       Date:  1995-03-27       Impact factor: 4.124

5.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

6.  Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family.

Authors:  J Liu; J Wess
Journal:  J Biol Chem       Date:  1996-04-12       Impact factor: 5.157

7.  Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.

Authors:  C Barbeis; M N Balestre; S Jard; E Tribollet; Y Arsenijevic; J J Dreifuss; K Bankowski; M Manning; W Y Chan; S S Schlosser
Journal:  Neuroendocrinology       Date:  1995-08       Impact factor: 4.914

8.  Cloning and characterization of the human V3 pituitary vasopressin receptor.

Authors:  Y de Keyzer; C Auzan; F Lenne; C Beldjord; M Thibonnier; X Bertagna; E Clauser
Journal:  FEBS Lett       Date:  1994-12-19       Impact factor: 4.124

9.  Effects of phospholipid unsaturation on the membrane/water interface: a molecular simulation study.

Authors:  K Murzyn; T Róg; G Jezierski; Y Takaoka; M Pasenkiewicz-Gierula
Journal:  Biophys J       Date:  2001-07       Impact factor: 4.033

10.  Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.

Authors:  T Sugimoto; M Saito; S Mochizuki; Y Watanabe; S Hashimoto; H Kawashima
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

View more
  1 in total

1.  Insights into the binding modes of human β₃-adrenergic receptor agonists with ligand-based and receptor-based methods.

Authors:  Fangfang Jin; Chunhua Lu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  Mol Divers       Date:  2011-03-20       Impact factor: 2.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.